GlaxoSmithKline (LON:GSK)‘s stock had its “hold” rating restated by equities researchers at Shore Capital in a research note issued on Wednesday, ThisIsMoney.Co.Uk reports.
Several other brokerages have also commented on GSK. Kepler Capital Markets upped their price objective on shares of GlaxoSmithKline from GBX 1,440 ($18.82) to GBX 1,540 ($20.12) and gave the stock a “hold” rating in a report on Tuesday, June 11th. HSBC set a €16.50 ($19.19) price objective on shares of UniCredit and gave the stock a “buy” rating in a report on Tuesday, May 14th. Liberum Capital restated a “hold” rating on shares of Daily Mail and General Trust P L C in a report on Tuesday, July 2nd. Credit Suisse Group began coverage on shares of Regeneron Pharmaceuticals in a report on Monday, May 20th. They issued a “neutral” rating and a $336.00 price objective on the stock. Finally, Jefferies Financial Group restated a “buy” rating and issued a C$15.00 price objective on shares of Aphria in a report on Friday, May 24th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of GBX 1,535.88 ($20.07).
Shares of GSK stock opened at GBX 1,628.22 ($21.28) on Wednesday. The business has a 50 day moving average of GBX 1,583.69. The company has a debt-to-equity ratio of 942.07, a quick ratio of 0.45 and a current ratio of 0.72. GlaxoSmithKline has a one year low of GBX 1,408.80 ($18.41) and a one year high of GBX 1,651 ($21.57). The firm has a market cap of $81.44 billion and a price-to-earnings ratio of 20.74.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Article: What Does Beta Mean In Stock Selection
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.